

About

HealthCare Royalty Partners is a global healthcare investment firm. Launched in 2007 by Founding Managing Directors Gregory B. Brown, M.D., Todd C. Davis and Clarke B. Fusch, HC Royalty specializes in making structured investments in commercial-stage healthcare companies and products. Our deep experience, broad and flexible investment platform and proven track record set HC Royalty apart from other firms.

We manage over \$2 billion in capital for a world-class list of investors which consist of public and corporate pension funds, financial institutions, insurance companies, funds-of-funds and university endowments. In July 2008, we closed on our first fund, HealthCare Royalty Partners, L.P. At closing this represented one of the largest inaugural healthcare-focused funds ever raised. In December 2011, we closed the largest private equity fund dedicated to healthcare royalty investments, HealthCare Royalty Partners II, L.P. and an affiliated fund.

Our broad-based internal team has deep investment skills, as well as financial, legal and operational expertise. Collectively, these individuals possess over 100 years of healthcare and financial experience specifically in principal investing, structured finance, healthcare industry senior management, Wall Street research, healthcare industry consulting, and scientific and clinical advisory work.

Approach

[Overview](#)[Companies](#)[Institutions](#)[Inventors](#)

Companies

HC Royalty maintains an active dialogue with both public and private companies related to products at varying stages of development and commercialization. We offer several financing options for companies, including the monetization of traditional passive royalties, creation of Synthetic Royalty® financings, and the purchase of structured debt and equity.

The innovative financing solutions that we deliver are non-dilutive, which allows companies to access capital to grow their businesses without diluting the stakes of current shareholders. Additionally, these financings are typically completed in a single-party transaction, which expedites timing and limits deal and process complexities. Limited debt covenants in these financings also allows companies to maintain operating and managerial flexibility. For many public companies, the capital markets attribute little or no value to existing royalty streams and a monetization can unlock that value. The cash can then be used to finance a product acquisition, a commercial infrastructure expansion, a new development opportunity or other strategic initiative.

These unique financing solutions reduce the future risk associated with a product, and provide companies immediate liquidity. They also allow a company to benefit from a product's potential today regardless of its eventual commercial performance.

HEALTHCARE

ROYALTY PARTNERS™

Portfolio

Select Investments:



<p>ArteFill Immediate Results. Lasting Improvement.</p> <p>Suneva Medical</p> <p>more info</p>	<p>Biosense Webster Catheters</p> <p>Johnson & Johnson</p> <p>more info</p>	<p>Cetrotide</p> <p>Merck Serono</p> <p>more info</p>	<p>eIGR Illumination Technology</p> <p>Invuity Inc.</p> <p>more info</p>
<p>Eligard</p> <p>Astellas Pharma Europe</p> <p>more info</p>	<p><i>Fenoglide</i> 120mg (ferofibrate) tablets & 40mg</p> <p>Santarus Inc.</p> <p>more info</p>	<p>KAMRA Rejuvenating everyday vision™</p> <p>AcuFocus</p> <p>more info</p>	<p>LEXIVA fosamprenavir calcium 700 MG TABLETS</p> <p>Viiv Healthcare/ GlaxoSmithKline</p> <p>more info</p>
<p>Licensing & Funded Research Program</p> <p>Dyax Corp.</p> <p>more info</p>	<p>LIPIFLOW</p> <p>TearScience</p> <p>more info</p>	<p>LYRICA PREGABALIN capsules</p> <p>Pfizer</p>	<p>MENINGITEC™</p> <p>Nuron Biotech</p> <p>more info</p>
<p>Once-daily 40 mg* Capsules</p> <p>ORACEA</p> <p>Galderma</p> <p>more info</p>	<p>Orphan Drug</p> <p>Undisclosed Deal</p>	<p>PROCYSBI</p> <p>Raptor Pharmaceuticals</p> <p>more info</p>	<p>Qutenza (capsaicin) 8% patch</p> <p>Astellas Pharma Europe</p> <p>more info</p>
<p>ReFissa Tosipium Chloride, USP (and/or) L255</p> <p>Suneva Medical</p> <p>more info</p>	<p>SANCTURA XR (trospium chloride extended release capsules)</p> <p>Allergan</p> <p>more info</p>	<p>Sumavel DosePro (sumatriptan injection)</p> <p>Zogenix/Mallinckrodt</p> <p>more info</p>	<p>Vaccine Product</p> <p>GlaxoSmithKline & Sanofi</p>

Previous Investments:



Lunesta
formerly sanofi-aventis



Nexterone
Baxter Healthcare



Rotarix®
oral rotavirus vaccine
GlaxoSmithKline



RotaTeq®
Merck



Zanaflex®
Acorda Therapeutics

News

Contact:
Kellie Walsh
914.315.6072

[EMAIL](#)

Press Releases

SUPERMUS TO RECEIVE \$30 MILLION IN NON-DILUTIVE ROYALTY DEAL

ROCKVILLE, MD. – July 8, 2014 – Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), today announced the execution agreement (“Agreement”) with HealthCare Royalty Partners (“HC Royalty”). Per the Agreement, HC Royalty will make a \$30 million cash payment to Supernus in consideration for acquiring from Supernus certain royalty and milestone rights related to the commercialization of Orenitram™ (drepiztrinal) Extended-Release Tablets by Supernus’ partner United Therapeutics Corporation. Supernus will retain full ownership of the Royalty Rights after a certain threshold has been reached per the terms of the Agreement.

“We are pleased to have completed this royalty transaction, which strengthens our balance sheet and enhances our financial flexibility,” said Jack Khattar, President and Chief Executive Officer of Supernus. “The transaction allows us to partially monetize our royalty stream from Orenitram™ for a significant cash consideration while positioning Supernus to further benefit from the future upside potential of the product.”

Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity. The product was recently launched by United Therapeutics Corporation (NASDAQ:UTHR) in the United States market. Supernus developed the extended release formulation of Orenitram under a Development and License Agreement with United Therapeutics using its EnSoTroI, novel osmotic technology platform. Per the license agreement between Supernus and United Therapeutics, Supernus is entitled to certain milestone fees and royalties (“Royalty Rights”) associated with the commercialization of the product worldwide.

“As a result of this royalty transaction, our cash position has been significantly strengthened giving us additional operational flexibility and expanding our capacity for potential business development activities,” added Jack A. Khattar.

“Orenitram is a meaningful advance in the treatment of pulmonary arterial hypertension, as the first FDA approved orally administered prostacyclin therapy,” commented Todd C. Davis, Founding Managing Director at HC Royalty. “We were pleased to structure a deal for Supernus that would enable them to financially benefit from the future success of Orenitram.”

For full patient information and full prescribing information, visit: http://www.orenitram.com/01c/pdf/Orenitram_Full_Prescribing_Information.pdf

Orenitram™ is a trademark of United Therapeutics Corporation.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxelstar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

About HealthCare Royalty Partners

HealthCare Royalty Partners is a global healthcare investment firm focused on providing financing solutions to healthcare companies and royalty owners with interests in approved pharmaceutical and medical device products. The firm's senior investment team has participated in over 50 royalty financings valued at over \$2 billion over the past decade. For more information, visit www.healthcareroyalty.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the potential net sales of Orenitram™ and United Therapeutics' willingness and ability to pay future royalties and milestone payments as they become due under the License Agreement with Supernus, or the significance of such payments. Actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, risks regarding United Therapeutics Corporation's ability to commercialize the product successfully, whether physicians will prescribe and patients will use the product, and competition in the market. For a further description of these and other risks facing the Company, please see the risk factors described in the Company's Annual Report Form 10-K that was filed with the United States Securities and Exchange Commission on March 21, 2014 under the caption "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update or revise these statements, except as may be required by law.